RxDoctor Payments Data

Ivan Arismendi Ortiz, MD

Internal Medicine · Springfield, MONPI 1366814634

Payments from drug & device makers

$1,931in general payments, 2019–2025

Across 111 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$430
  • Lilly USA, LLC$394
  • Abbott$346
  • GSK$126
  • Boehringer Ingelheim$117
  • Novo Nordisk$114
  • plus $405 from 12 others

What the payments were for

  • Food & beverage$1,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,931 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$50,692
Medicare patients
128
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$48,437
RybelsusSemaglutide17$28,521
OzempicSemaglutide30$27,791
MounjaroTirzepatide24$27,257
JardianceEmpagliflozin19$23,584
TrulicityDulaglutide11$12,557
Tresiba Flextouch U-100Insulin Degludec25$11,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,384
ArexvyRsvpref3 Antigen/As01e/Pf19$5,442
SymbicortBudesonide/Formoterol Fumarate15$3,642
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,262
Gabapentin273$3,154
Pravastatin Sodium231$1,930
Albuterol Sulfate HfaAlbuterol Sulfate87$1,784
Duloxetine Hcl119$1,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$114$56,31247 claims
PfizerEliquis$77$48,43763 claims
Lilly USA, LLCMounjaro, Trulicity$394$39,81435 claims
Boehringer IngelheimJardiance$117$23,58419 claims
GSKTrelegy Ellipta, Arexvy$126$13,82632 claims
AstraZenecaSymbicort$430$3,64215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →